The breakthroughs emerging from Pfizer’s pipeline mean nothing if patients are not able to afford them. Within a month of taking leadership as CEO of Pfizer, Dr. Albert Bourla became a central figure in one of America’s most important policy discussions: how to ensure people have access to the medicines they need.Testifying at the February 26, 2019, Senate Finance Committee hearing on drug pricing, Dr. Bourla put forth four pillars for patient affordability: passing rebates directly to patients at the point of sale; encouraging broader adoption of outcomes-based payment models; capping seniors’ out-of-pocket costs in Medicare Part D; and incentivizing the use of lower-cost biosimilars in Medicare.

“Drug pricing is a priority conversation – not just among policymakers but among patients,” says Angela Hwang, Group President, Pfizer Biopharmaceuticals Group. “Our part in helping to shape that conversation is essential to the lives we are trying to impact every day. The creation of new patient affordability solutions – not just in 2019 but into 2020 and the years to come – is key.”

Pfizer leadership and employees at all levels continue to advocate for policy solutions to achieve a health care system that puts patients – and their health – first.